Macrolides: A Canadian infectious disease society position paper

Canadian Journal of Infectious Diseases

Volumn 12, Issue 4, 2001, Pages 218-231

  McKenna, S ^a   Evans, G A ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Azithromycin; Clarithromycin; Erythromycin; Macrolides; Review; Therapeutic use

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CEFACLOR; CEFIXIME; CLARITHROMYCIN; ERYTHROMYCIN; MACROLIDE; PENICILLIN V;

ABDOMINAL PAIN; ANTIMICROBIAL ACTIVITY; BIOAVAILABILITY; DIARRHEA; DRUG MECHANISM; DRUG TOLERABILITY; DYSPEPSIA; GASTROINTESTINAL MOTILITY; HUMAN; INFECTION; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; REVIEW; STREPTOCOCCUS PNEUMONIAE; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

EID: 0034752054     PISSN: 11802332     EISSN: None     Source Type: Journal    
DOI: 10.1155/2001/657353     Document Type: Review

References (97)

1. Structure and activity
2. Clarithromycin: A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential
3. The pharmacokinetics of azithromycin
4. Resistance to macrolides, azalides, and streptogramins
5. Molecular mechanisms of resistance to commonly used non-betalactam drugs in Streptococcus pneumoniae
6. Trends and significance of antimicrobial resistance in respiratory pathogens
7. Incidence of mefA and ermB among macrolide resistant Streptococcus pneumoniae (SPN) isolated in Canada during 1998 and 1999
8. In vitro activity against Gram-positive and Gram-negative bacteria
9. Activities of azithromycin and clarithromycin against nontuberculous mycobacteria in beige mice
10. Effect of pH on radiometric MICs of clarithromycin against 18 species of mycobacteria
11. The new macrolides: Azithromycin and clarithromycin
12. Azithromycin: A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy
13. Erythromycin-induced ototoxicity: A case report and review of the literature
14. Erythromycin, clarithromycin, and azithromycin: Are the differences real?
15. Concentrations of azithromycin in human tonsillar tissue
16. Clarithromycin and azithromycin: New macrolide antibiotics
17. Comparison of clarithromycin and penicillin VK suspensions in the treatment of children with streptococcal pharyngitis and review of currently available alternative antibiotic therapies
18. Evaluation of the efficacy, safety and toleration of azithromycin vs penicillin V in the treatment of acute streptococcal pharyngitis in children: Results of a multicenter, open comparative study
19. Clarithromycin suspension vs penicillin V suspension in children with streptococcal pharyngitis
20. A comparative study of clarithromycin and penicillin VK in the treatment of outpatients with streptococcal pharyngitis
21. Comparative efficacy and safety of 3-day azithromycin and 10-day penicillin V treatment of group A beta-hemolytic streptococcal pharyngitis in children
22. Management of pediatric patients with group A beta-hemolytic Streptococcus pharyngitis: Treatment options
23. Treatment of streptococcal pharyngitis in children with five days of azithromycin suspension
24. Multicenter comparison of clarithromycin and amoxicillin in the treatment of acute maxillary sinusitis
25. Efficacy of clarithromycin vs amoxicillin/clavulanate in the treatment of acute maxillary sinusitis
26. An open-label, non-comparative study to evaluate the efficacy, safety, and tolerability of azithromycin in the treatment of patients with acute sinusitis
27. A comparison of the efficacy, tolerability and safety of azithromycin and co-amoxiclav in the treatment of sinusitis in adults
28. Multicentre comparative study of the efficacy and safety of azithromycin compared with amoxicillin/clavulanic acid in the treatment of paediatric patients with otitis media
29. Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs azithromycin in acute otitis media
30. Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children
31. Clarithromycin vs amoxicillin suspensions in the treatment of pediatric patients with acute otitis media
32. A comparative study of clarithromycin and amoxycillin suspensions in the treatment of pediatric patients with acute otitis media
33. Comparative study of the safety and efficacy of clarithromycin and amoxicillin-clavulanate in the treatment of acute otitis media in children
34. Comparative safety and efficacy of clarithromycin and amoxicillin/clavulanate in the treatment of acute otitis media in children
35. Clarithromycin and cefaclor suspensions in the treatment of acute otitis media in children
36. Clarithromycin versus cefaclor for the treatment of mild-to-moderate acute bacterial bronchitis
37. Clarithromycin 250 mg bid for 5 or 10 days in the treatment of adult patients with purulent bronchitis
38. Efficacy of oral ciprofloxacin vs clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis
39. Etiology, susceptibility, and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: Ciprofloxacin 750 mg bid versus clarithromycin 500 mg bid
40. Efficacy and safety of clarithromycin compared to cefixime as outpatient treatment of lower respiratory tract infections
41. Clarithromycin versus cefaclor in lower respiratory tract infections
42. Comparison of azithromycin versus clarithromycin in the treatment of patients with lower respiratory tract infections
43. Comparison of azithromycin and co-amoxiclav in the treatment of acute tracheobronchitis and acute infectious exacerbations of chronic bronchitis in adults
44. Efficacy of short-term treatment of pertussis with clarlthromycin and azithromycin
45. Short-term treatment of pertussis with azithromycin in infants and young children
46. A randomized comparative study on the safety and efficacy of clarithromycin and erythromycin in treating community-acquired pneumonia
47. Treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing clarithromycin with erythromycin
48. Efficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia
49. Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia
50. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients
51. Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia
52. Efficacy of a three-day course of azithromycin in the treatment of community-acquired pneumococcal pneumonia
53. Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children
54. Clarithromycin in the treatment of skin and skin structure infections: Two multicenter clinical studies
55. Comparative safety and efficacy of clarithromycin and cefadroxil suspensions in the treatment of mild to moderate skin and skin structure infections in children
56. Comparative studies of azithromycin in skin and soft-tissue infections and sexually transmitted infections by Neisseria and Chlamydia species
57. Azithromycin, erythromycin and cloxacillin in the treatment of infections of skin and associated soft tissues
58. Double-blind, double-dummy comparison of azithromycin and cephalexin in the treatment of skin and skin structure infections
59. Azithromycin compared with cephalexin in the treatment of skin and skin structure infections
60. A comparative study of the efficacy, safety and tolerability of azithromycin and cefaclor in the treatment of children with acute skin and/or soft tissue infections
61. Single dose azithromycin treatment of gonorrhea and infections caused by C trachomatis and U urealyticum in men
62. Chlamydial cervicitis and urethritis: Single dose treatment compared with doxycycline for seven days in community based practices
63. Azithromycin for empirical treatment of the nongonococcal urethritis syndrome in men. A randomized double-blind study
64. A preliminary study of clarithromycin versus doxycycline in the treatment of nongonococcal urethritis and mucopurulent cervicitis
65. Single-dose azithromycin for chlamydia in pregnant women
66. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome
67. Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial
68. Prophylaxis against disseminated Mycobactertum avium complex with weekly azithromycin, daily rifabutin, or both
69. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS
70. Clarithromycin and other antimicrobial agents in the treatment of disseminated Mycobacterium avium infections in patients with acquired immunodeficiency syndrome
71. Initial clarithromycin monotherapy for Mycobacterium avium complex lung disease
72. Clarithromycin against Mycobacterium avium complex infections
73. A randomized evaluation of ethambutol for prevention of relapse and drug resistance during treatment of Mycobacterium avium complex bacteremia with clarithromycin-based combination therapy
74. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: Rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin
75. Randomized, open-label trial of azichromycin plus ethambutol vs clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection
76. Diagnosis and treatment of disease caused by nontuberculous mycobacteria
77. Clinical trial of clarithromycin for cutaneous (disseminated) infection due to Mycobacterium chelonae
78. Clinical trial of clarithromycin for lepromatous leprosy
79. Omeprazole plus antibiotics in the eradication of Helicobacter pylori infection: A meta-regression analysis of randomized, controlled trials
80. Evaluation of treatment regimens to cure Helicobacter pylori infection - A meta-analysis
81. The importance of clarithromycin dose in the management of Helicobacter pylori infection: A meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole
82. Antimicrobial treatment of H pylori infection - A pooled efficacy analysis of eradication therapies
83. Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori
84. Review of Helicobacter pylori eradication regimens
85. Azithromycin: A critical review of the first azalide antibiotic and its role in pediatric practice
86. Newer macrolides offer some advantages over erythromycin
87. Toleration of intravenous azithromycin
88. Intravenous azithromycin-induced ototoxicity
89. Pharmacokinetics and pharmacodynamics of intravenous and oral azithromycin: Enhanced tissue activity and minimal drug interactions
90. Clinical practice guidelines for the care and treatment of breast cancer: A Canadian consensus document
91. Prevention of bacterial endocarditis. Recommendations by the American Heart Association
92. In vitro activity against Mycoplasma spp and intracellular organisms
93. In-vitro activity of quinolones and macrolides against mycobacteria